Recent Updates
Recently added Catalysts

HMPL-A83

Phase 1

Advanced Tumors | Small molecule | Oncology |HUTCHMED (China) Limited|Last Updated: Jun 17, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05429008A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant NeoplasmPHASE1 COMPLETED 40 — — Jul 1, 2022Apr 1, 2025Jun 17, 2025 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
HMPL-A83 injectionDRUGDay 1,8,15,22 dose; 28 day treatment cycles.
Unlock Study Design Details
Competitive Landscape -Brain Tumors 139 trials
CompanyTickerTrialsLead PhaseDrugs
NovoCure Ltd.NVCR5PHASE3Temozolomide, Pembrolizumab, Poly-ICLC, Peptides, Concurrent Optune and RT followed by Optune System alone
Jazz Pharmaceuticals Public Limited CompanyJAZZ4PHASE3Dordaviprone, Everolimus, ONC201, JZP3507, ONC206
Day One Biopharmaceuticals, Inc.DAWN2PHASE3Tovorafenib, Chemotherapeutic Agent
Nuvation Bio, Inc. Class ANUVB1PHASE3safusidenib
Tango Therapeutics, Inc.TNGX3PHASE3Vorasidenib, Temozolomide, TNG456, abemaciclib
Telix Pharmaceuticals Limited Sponsored ADRTLX2PHASE3TLX-101-Tx + Lomustine, 131I-IPA
Eli Lilly and CompanyLLY3PHASE2Abemaciclib, Temozolomide, LY3410738, Gemcitabine, Cisplatin
Pfizer Inc.PFE3PHASE2Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide
Novartis AG Sponsored ADRNVS3PHASE2Dabrafenib, Trametinib, Lu-NeoB, Ga-NeoB, Lu-DOTA-TATE
NeOnc Technologies Holdings, Inc.NTHI4PHASE2NEO100, NEO212, Ipilimumab, Pembrolizumab, Nivolumab
Exelixis, Inc.EXEL2PHASE2Zanzalintinib, Cabozantinib
CNS Pharmaceuticals, Inc.CNSP1PHASE2Berubicin, Lomustine
Black Diamond Therapeutics, Inc.BDTX1PHASE2silevertinib in combination with temozolomide, temozolomide
Actuate Therapeutics, Inc.ACTU1PHASE29-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin.
Rigel Pharmaceuticals, Inc.RIGL1PHASE2Olutasidenib + TMZ
Apollomics Inc. Class AAPLM1PHASE2APL-101
ImmunityBio IncIBRX1PHASE2Bevacizumab, PD-L1 t-haNK, N-803
Cooper Companies, Inc.COO1PHASE2Pre-radiation temozolomide.
Incyte CorporationINCY1PHASE2Ruxolitinib, Temozolomide
AstraZeneca PLCAZN2PHASE1AZD1390, Olaparib, Durvalumab, Physicians Choice systemic chemotherapy
Unlock Competitive Intelligence